{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:11:25Z","timestamp":1777594285870,"version":"3.51.4"},"reference-count":174,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PNT"],"published-print":{"date-parts":[[2020,10,8]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Dry eye disease (DED) is a common multifactorial disease linked to the tears\/ocular\nsurface leading to eye discomfort, ocular surface damage, and visual disturbance. Antiinflammatory\nagents (steroids and cyclosporine A), hormonal therapy, antibiotics, nerve growth\nfactors, essential fatty acids are used as treatment options of DED. Current therapies attempt to\nreduce the ocular discomfort by producing lubrication and stimulating gland\/nerve(s) associated\nwith tear production, without providing a permanent cure for dry eye. Nanocarrier systems\nshow a great promise to revolutionize drug delivery in DED, offering many advantages such as\nsite specific and sustained delivery of therapeutic agents. This review presents an overview,\npathophysiology, prevalence and etiology of DED, with an emphasis on preclinical and clinical\nstudies involving the use of nanocarrier systems in treating DED.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Lay Summary:<\/jats:title>\n<jats:p>Lay Summary: Dry eye disease (DED) is a multifactorial disease associated with tear deficiency\nor excessive tear evaporation. There are several review articles that summarize DED, disease\nsymptoms, causes and treatment approaches. Nanocarrier systems show a great promise to\nrevolutionize drug delivery in DED, offering many advantages such as site specific and sustained\ndelivery of therapeutic agents. Very few review articles summarize the findings on the\nuse of nanotherapeutics in DED. In this review, we have exclusively discussed the preclinical\nand clinical studies of nanotherapeutics in DED therapy. This information will be attractive to\nboth academic and pharmaceutical industry researchers working in DED therapeutics.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2211738508666200628034227","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T06:18:28Z","timestamp":1593497908000},"page":"258-289","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Role of Nano-ophthalmology in Treating Dry Eye Disease"],"prefix":"10.2174","volume":"8","author":[{"given":"Subramanian","family":"Natesan","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, University College of Engineering, BIT Campus, Anna University, Tiruchirappalli, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai H.S.","family":"Boddu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkateshwaran","family":"Krishnaswami","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, University College of Engineering, BIT Campus, Anna University, Tiruchirappalli, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moyad","family":"Shahwan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"192","volume":"6","author":"Javadi M-A.","year":"2011","unstructured":"Javadi M-A.; Feizi S.; Dry eye syndrome. J Ophthalmic Vis Res 2011,6(3),192-198","journal-title":"J Ophthalmic Vis Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3238\/arztebl.2015.0071","volume":"112","author":"Messmer E.M.","year":"2015","unstructured":"Messmer E.M.; The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 2015,112(5),71-81","journal-title":"Dtsch Arztebl Int"},{"key":"ref=3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215130","volume":"14","author":"Shimizu E.","year":"2019","unstructured":"Shimizu E.; Ogawa Y.; Yazu H.; \u201cSmart Eye Camera\u201d: an innovative technique to evaluate tear film breakup time in a murine dry eye disease model. PLoS One 2019,14(5)","journal-title":"PLoS One"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1590\/S0034-72802013000400005","volume":"72","year":"2013","unstructured":"Fulg\u00eancio GdO, Saliba JB, Fialho SL, J\u00fanior C, da Silva A. Cyclosporine-loaded delivery system for the treatment of keratoconjunctivitis sicca: a pilot study. Rev Bras Oftalmol 2013,72(4),232-236","journal-title":"Rev Bras Oftalmol"},{"key":"ref=5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208420","volume":"13","author":"Garcia D.M.","year":"2018","unstructured":"Garcia D.M.; Reis de Oliveira F.; M\u00f3dulo C.M.; Is Sj\u00f6gren\u2019s syndrome dry eye similar to dry eye caused by other etiologies? Discriminating different diseases by dry eye tests. PLoS One 2018,13(12)","journal-title":"PLoS One"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1089\/jop.2017.0052","volume":"33","author":"Garrigue J-S.","year":"2017","unstructured":"Garrigue J-S.; Amrane M.; Faure M-O.; Holopainen J.M.; Tong L.; Relevance of lipid-based products in the management of dry eye disease. J Ocul Pharmacol Ther 2017,33(9),647-661","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/pharmaceutics10010028","volume":"10","author":"Bachu R.D.","year":"2018","unstructured":"Bachu R.D.; Chowdhury P.; Al-Saedi Z.H.F.; Karla P.K.; Boddu S.H.S.; Ocular drug delivery barriers-role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics 2018,10(1),28","journal-title":"Pharmaceutics"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/polym10040425","volume":"10","author":"Vicario-de-la-Torre M.","year":"2018","unstructured":"Vicario-de-la-Torre M.; Caballo-Gonz\u00e1lez M.; Vico E.; Novel nano-liposome formulation for dry eyes with components similar to the preocular tear film. Polymers (Basel) 2018,10(4),425","journal-title":"Polymers (Basel)"},{"key":"ref=9","first-page":"1419","volume":"8","author":"Moshirfar M.","year":"2014","unstructured":"Moshirfar M.; Pierson K.; Hanamaikai K.; Santiago-Caban L.; Muthappan V.; Passi S.F.; Artificial tears potpourri: a literature review. Clin Ophthalmol 2014,8,1419-1433","journal-title":"Clin Ophthalmol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4103\/0976-500X.195920","volume":"7","author":"Abidi A.","year":"2016","unstructured":"Abidi A.; Shukla P.; Ahmad A.; Lifitegrast: a novel drug for treatment of dry eye disease. J Pharmacol Pharmacother 2016,7(4),194-198","journal-title":"J Pharmacol Pharmacother"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/archopht.126.8.1046","volume":"126","author":"Perry H.D.","year":"2008","unstructured":"Perry H.D.; Solomon R.; Donnenfeld E.D.; Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol 2008,126(8),1046-1050","journal-title":"Arch Ophthalmol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40123-015-0038-y","volume":"4","author":"Vickers L.A.","year":"2015","unstructured":"Vickers L.A.; Gupta P.K.; The future of dry eye treatment: a glance into the therapeutic pipeline. Ophthalmol Ther 2015,4(2),69-78","journal-title":"Ophthalmol Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/ICO.0b013e3181a16472","volume":"28","author":"Dastjerdi M.H.","year":"2009","unstructured":"Dastjerdi M.H.; Hamrah P.; Dana R.; High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 2009,28(10),1091-1096","journal-title":"Cornea"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","volume":"28117","author":"Lallemand F.","year":"2017","unstructured":"Lallemand F.; Schmitt M.; Bourges J-L.; Gurny R.; Benita S.; Garrigue J-S.; Cyclosporine a delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm 2017,28117,14-28","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","volume":"26","author":"Gaudana R.","year":"2009","unstructured":"Gaudana R.; Jwala J.; Boddu S.H.S.; Mitra A.K.; Recent perspectives in ocular drug delivery. Pharm Res 2009,26(5),1197-1216","journal-title":"Pharm Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/jop.2016.0013","volume":"32","author":"Al-Saedi Z.H.","year":"2016","unstructured":"Al-Saedi Z.H.; Alzhrani R.M.; Boddu S.H.; Formulation and in vitro evaluation of cyclosporine-A inserts prepared using hydroxypropyl methylcellulose for treating dry eye disease. J Ocul Pharmacol Ther 2016,32(7),451-462","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=17","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-13-8538-4","author":"Gupta P.","year":"2019","unstructured":"Gupta P.; Trattler W.; Levinson B.; Rostov A.T.; Available at: LACRISERT\u00ae(hydroxypropyl cellulose ophthalmic insert) in current practice: reflections on a longstanding therapy for moderate to severe dry eye 2019","journal-title":"LACRISERT\u00ae(hydroxypropyl cellulose ophthalmic insert) in current practice: reflections on a longstanding therapy for moderate to severe dry eye"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.preteyeres.2013.04.001","volume":"36","author":"Kompella U.B.","year":"2013","unstructured":"Kompella U.B.; Amrite A.C.; Pacha Ravi R.; Durazo S.A.; Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res 2013,36,172-198","journal-title":"Prog Retin Eye Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ejpb.2015.02.019","volume":"0195","author":"Reimondez-Troiti\u00f1o S.","year":"2015","unstructured":"Reimondez-Troiti\u00f1o S.; Csaba N.; Alonso M.J.; de la Fuente M.; Nanotherapies for the treatment of ocular diseases. Eur J Pharm Biopharm 2015,0195,279-293","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.3390\/ijms19092830","volume":"19","author":"Tsai C-H.","year":"2018","unstructured":"Tsai C-H.; Wang P-Y.; Lin I.C.; Huang H.; Liu G-S.; Tseng C-L.; Ocular drug delivery: role of degradable polymeric nanocarriers for ophthalmic application. Int J Mol Sci 2018,19(9),2830","journal-title":"Int J Mol Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1021\/nn4046024","volume":"8","author":"Natarajan J.V.","year":"2014","unstructured":"Natarajan J.V.; Darwitan A.; Barathi V.A.; Sustained drug release in nanomedicine: a long-acting nanocarrier-based formulation for glaucoma. ACS Nano 2014,8(1),419-429","journal-title":"ACS Nano"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/jphp.12075","volume":"66","author":"Daull P.","year":"2014","unstructured":"Daull P.; Lallemand F.; Garrigue J.S.; Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol 2014,66(4),531-541","journal-title":"J Pharm Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2478\/acph-2019-0054","volume":"69","author":"Dukovski B.J.","year":"2019","unstructured":"Dukovski B.J.; Bra\u010dko A.; \u0160are M.; Pepi\u0107 I.; Lovri\u0107 J.; In vitro evaluation of stearylamine cationic nanoemulsions for improved ocular drug delivery. Acta Pharm 2019,69(4),621-634","journal-title":"Acta Pharm"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11095-018-2556-5","volume":"36","author":"Mandal A.","year":"2019","unstructured":"Mandal A.; Gote V.; Pal D.; Ogundele A.; Mitra A.K.; Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (CEQUA\u00ae) for dry eye disease. Pharm Res 2019,36(2),36","journal-title":"Pharm Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-3-319-47691-9_5","author":"Bennett L.","year":"2016","unstructured":"Bennett L.;  Topical versus systemic ocular drug delivery ocular drug delivery: advances, challenges and applications 2016,53-74","journal-title":"Topical versus systemic ocular drug delivery ocular drug delivery: advances, challenges and applications"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/ijms18071558","volume":"18","author":"Georgiev G.A.","year":"2017","unstructured":"Georgiev G.A.; Yokoi N.; Nencheva Y.; Peev N.; Daull P.; Surface chemistry interactions of cationorm with films by human meibum and tear film compounds. Int J Mol Sci 2017,18(7),1558","journal-title":"Int J Mol Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40267-016-0319-0","volume":"32","author":"Lyseng-Williamson K.A.","year":"2016","unstructured":"Lyseng-Williamson K.A.; Cationorm\u00ae(cationic emulsion eye drops) in dry eye disease: a guide to its use. Drugs Ther Perspect 2016,32(8),317-322","journal-title":"Drugs Ther Perspect"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","volume":"26","author":"Gaudana R.","year":"2009","unstructured":"Gaudana R.; Jwala J.; Boddu S.H.; Mitra A.K.; Recent perspectives in ocular drug delivery. Pharm Res 2009,26(5),1197-1216","journal-title":"Pharm Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.drudis.2007.10.021","volume":"13","author":"Sahoo S.K.","year":"2008","unstructured":"Sahoo S.K.; Dilnawaz F.; Krishnakumar S.; Nanotechnology in ocular drug delivery. Drug Discov Today 2008,13(3-4),144-151","journal-title":"Drug Discov Today"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40199-018-00235-2","volume":"27","author":"Ahmadi Tehrani A.","year":"2019","unstructured":"Ahmadi Tehrani A.; Omranpoor M.M.; Vatanara A.; Seyedabadi M.; Ramezani V.; Formation of nanosuspensions in bottom-up approach: theories and optimization. Daru 2019,27(1),451-473","journal-title":"Daru"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrd1494","volume":"013","author":"Rabinow B.E.","year":"2004","unstructured":"Rabinow B.E.; Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004,013(9),785-796","journal-title":"Nat Rev Drug Discov"},{"key":"ref=32","first-page":"491","volume":"66","author":"Kim J.H.","year":"2011","unstructured":"Kim J.H.; Jang S.W.; Han S.D.; Hwang H.D.; Choi H-G.; Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods. Pharmazie 2011,66(7),491-495","journal-title":"Pharmazie"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ejps.2013.07.002","volume":"50","author":"Luschmann C.","year":"2013","unstructured":"Luschmann C.; Tessmar J.; Schoeberl S.; Developing an in situ nanosuspension: a novel approach towards the efficient administration of poorly soluble drugs at the anterior eye. Eur J Pharm Sci 2013,50(3-4),385-392","journal-title":"Eur J Pharm Sci"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","volume":"147","author":"Kim E.C.","year":"2009","unstructured":"Kim E.C.; Choi J-S.; Joo C-K.; A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J of Ophthalmol 2009,147(2),206-213","journal-title":"Am J of Ophthalmol"},{"key":"ref=35","first-page":"283","volume":"2","author":"Akhgari A.","year":"2015","unstructured":"Akhgari A.; Saremi H.; Khodayar M.J.; Preparation and evaluation of vitamin A nanosuspension as a novel ocular drug delivery. Nanomed J 2015,2(4),283-290","journal-title":"Nanomed J"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0169-409X(00)00103-4","volume":"45","author":"Lawrence M.J.","year":"2000","unstructured":"Lawrence M.J.; Rees G.D.; Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000,45(1),89-121","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1442-9071.2004.00914.x","volume":"32","author":"Fialho S.L.","year":"2004","unstructured":"Fialho S.L.; da Silva-Cunha A.; New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Exp Ophthalmol 2004,32(6),626-632","journal-title":"Clin Exp Ophthalmol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1350-9462(01)00017-9","volume":"21","author":"Vandamme T.F.","year":"2002","unstructured":"Vandamme T.F.; Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res 2002,21(1),15-34","journal-title":"Prog Retin Eye Res"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.colsurfb.2018.09.063","volume":"02173","author":"Lidich N.","year":"2019","unstructured":"Lidich N.; Garti-Levy S.; Aserin A.; Garti N.; Potentiality of microemulsion systems in treatment of ophthalmic disorders: keratoconus and dry eye syndrome - in vivo study. Colloids Surf B Biointerfaces 2019,02173,226-232","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=40","author":"Warouw H","unstructured":"Warouw H; Ekantini R; Widayanti TW;  The effectiveness of lipofilm microemulsion eye drops in dry eye syndrome by enhancing the tear film quality. Jurnal Oftalmologi Indonesia (JOI) 2009; 7(2): 57i61","journal-title":"Jurnal Oftalmologi Indonesia (JOI) 2009; 7(2): 57i61"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1167\/tvst.7.5.24","volume":"7","author":"Coursey T.G.","year":"2018","unstructured":"Coursey T.G.; Wassel R.A.; Quiambao A.B.; Farjo R.A.; Once-daily cyclosporine-A-MiDROPS for treatment of dry eye disease. Transl Vis Sci Techn 2018,7(5),24","journal-title":"Transl Vis Sci Techn"},{"key":"ref=42","author":"G\u00fcnther B.","year":"2017","unstructured":"G\u00fcnther B.; Scherer D.; Pettigrew A.;  Semifluorinated alkane compositions.  United States patent US 9,770,508 2017","journal-title":"United States patent US 9,770,508"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1167\/iovs.18-24758","volume":"59","author":"Downie L.E.","year":"2018","unstructured":"Downie L.E.; Gad A.; Wong C.Y.; Modulating contact lens discomfort with anti-inflammatory approaches: a randomized controlled trial. Invest Ophthalmol Vis Sci 2018,59(8),3755-3766","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=44","first-page":"219","author":"Vadlapudi A.D.","year":"2015","unstructured":"Vadlapudi A.D.; Cholkar K.; Dasari S.R.; Mitra A.K.;  Ocular drug delivery 2015,219-263","journal-title":"Ocular drug delivery"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2003.09.016","volume":"269","author":"Kaur I.P.","year":"2004","unstructured":"Kaur I.P.; Garg A.; Singla A.K.; Aggarwal D.; Vesicular systems in ocular drug delivery: an overview. Int J Pharm 2004,269(1),1-14","journal-title":"Int J Pharm"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ICO.0b013e31821b71e6","volume":"31","author":"McCann L.C.","year":"2012","unstructured":"McCann L.C.; Tomlinson A.; Pearce E.I.; Papa V.; Effectiveness of artificial tears in the management of evaporative dry eye. Cornea 2012,31(1),1-5","journal-title":"Cornea"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.clae.2017.11.004","volume":"41","author":"Acar D.","year":"2018","unstructured":"Acar D.; Molina-Mart\u00ednez I.T.; G\u00f3mez-Ballesteros M.; Guzm\u00e1n-Navarro M.; Ben\u00edtez-Del-Castillo J.M.; Herrero-Vanrell R.; Novel liposome-based and in situ gelling artificial tear formulation for dry eye disease treatment. Cont Lens Anterior Eye 2018,41(1),93-96","journal-title":"Cont Lens Anterior Eye"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF00137134","volume":"12","author":"Alghadyan A.A.","year":"1988","unstructured":"Alghadyan A.A.; Peyman G.A.; Khoobehi B.; Liu K-R.; Liposome-bound cyclosporine: retinal toxicity after intravitreal injection. Int Ophthalmol 1988,12(2),105-107","journal-title":"Int Ophthalmol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fchem.2017.00103","volume":"5","author":"Gomaa A.I.","year":"2017","unstructured":"Gomaa A.I.; Martinent C.; Hammami R.; Fliss I.; Subirade M.; Dual coating of liposomes as encapsulating matrix of antimicrobial peptides: development and characterization. Front Chem 2017,5,103","journal-title":"Front Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1089\/jop.2017.0052","volume":"33","author":"Garrigue J-S.","year":"2017","unstructured":"Garrigue J-S.; Amrane M.; Faure M-O.; Holopainen J.M.; Tong L.; Relevance of lipid-based products in the management of dry eye disease. J Ocul Pharmacol Ther 2017,33(9),647-661","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3109\/10717544.2011.621994","volume":"19","author":"Li N.","year":"2012","unstructured":"Li N.; Zhuang C-Y.; Wang M.; Sui C-G.; Pan W-S.; Low molecular weight chitosan-coated liposomes for ocular drug delivery: in vitro and in vivo studies. Drug Deliv 2012,19(1),28-35","journal-title":"Drug Deliv"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1089\/jop.2006.130","volume":"23","author":"Buech G.","year":"2007","unstructured":"Buech G.; Bertelmann E.; Pleyer U.; Siebenbrodt I.; Borchert H-H.; Formulation of sirolimus eye drops and corneal permeation studies. J Ocul Pharmacol Ther 2007,23(3),292-303","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nri2546","volume":"9","author":"Thomson A.W.","year":"2009","unstructured":"Thomson A.W.; Turnquist H.R.; Raimondi G.; Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009,9(5),324-337","journal-title":"Nat Rev Immunol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/jop.2015.0032","volume":"32","author":"Linares-Alba M.A.","year":"2016","unstructured":"Linares-Alba M.A.; G\u00f3mez-Guajardo M.B.; Fonzar J.F.; Brooks D.E.; Garc\u00eda-S\u00e1nchez G.A.; Bernad-Bernad M.J.; Preformulation studies of a liposomal formulation containing sirolimus for the treatment of dry eye disease. J Ocul Pharmacol Ther 2016,32(1),11-22","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=55","first-page":"3791","volume":"9","author":"Karn P.R.","year":"2014","unstructured":"Karn P.R.; Kim H.D.; Kang H.; Sun B.K.; Jin S-E.; Hwang S-J.; Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin a emulsion. Int J Nanomedicine 2014,9,3791-3800","journal-title":"Int J Nanomedicine"},{"key":"ref=56","author":"Kala Pharmaceuticals I.","unstructured":"Kala Pharmaceuticals I.; , Available at: Focus on Eye Care","journal-title":"Focus on Eye Care"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/wnan.1272","volume":"6","author":"Vaishya R.D.","year":"2014","unstructured":"Vaishya R.D.; Khurana V.; Patel S.; Mitra A.K.; Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2014,6(5),422-437","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2217\/nnm.10.10","volume":"5","author":"Trivedi R.","year":"2010","unstructured":"Trivedi R.; Kompella U.B.; Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond) 2010,5(3),485-505","journal-title":"Nanomedicine (Lond)"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0168-3659(01)00299-1","volume":"73","author":"Torchilin V.P.","year":"2001","unstructured":"Torchilin V.P.; Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001,73(2-3),137-172","journal-title":"J Control Release"},{"key":"ref=60","first-page":"147","volume":"8","author":"Rangel-Yagui C.O.","year":"2005","unstructured":"Rangel-Yagui C.O.; Pessoa A.; Tavares L.C.; Micellar solubilization of drugs. J Pharm Pharm Sci 2005,8(2),147-165","journal-title":"J Pharm Pharm Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/1877912311202020082","volume":"2","author":"Cholkar K.","year":"2012","unstructured":"Cholkar K.; Patel A.; Vadlapudi A.D.; Mitra A.K.K.; Mitra A.; Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Pat Nanomed 2012,2(2),82-95","journal-title":"Recent Pat Nanomed"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1088\/0034-4885\/53\/3\/002","volume":"53","author":"Chevalier Y.","year":"1990","unstructured":"Chevalier Y.; Zemb T.; The structure of micelles and microemulsions. Rep Prog Phys 1990,53(3),279","journal-title":"Rep Prog Phys"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1023\/A:1013671819604","volume":"19","author":"Kuwano M.","year":"2002","unstructured":"Kuwano M.; Ibuki H.; Morikawa N.; Ota A.; Kawashima Y.; Cyclosporine A formulation affects its ocular distribution in rabbits. Pharm Res 2002,19(1),108-111","journal-title":"Pharm Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1021\/jp901228v","volume":"113","author":"Sammalkorpi M.","year":"2009","unstructured":"Sammalkorpi M.; Karttunen M.; Haataja M.; Ionic surfactant aggregates in saline solutions: sodium dodecyl sulfate (SDS) in the presence of excess sodium chloride (NaCl) or calcium chloride (CaCl(2)). J Phys Chem B 2009,113(17),5863-5870","journal-title":"J Phys Chem B"},{"key":"ref=65","doi-asserted-by":"publisher","DOI":"10.1002\/9781118228920","author":"Rosen M.J.","year":"2012","unstructured":"Rosen M.J.; Kunjappu J.T.;  Surfactants and interfacial phenomena 2012","journal-title":"Surfactants and interfacial phenomena"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/ICO.0b013e3182a7f3bf","volume":"33","author":"Luschmann C.","year":"2014","unstructured":"Luschmann C.; Tessmar J.; Schoeberl S.; Strau\u00df O.; Luschmann K.; Goepferich A.; Self-assembling colloidal system for the ocular administration of cyclosporine A. Cornea 2014,33(1),77-81","journal-title":"Cornea"},{"key":"ref=67","first-page":"2921","volume":"11","author":"Kang H.","year":"2016","unstructured":"Kang H.; Cha K-H.; Cho W.; Cyclosporine Amicellar delivery system for dry eyes. Int J Nanomedicine 2016,11,2921-2933","journal-title":"Int J Nanomedicine"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1167\/iovs.16-19159","volume":"58","author":"Shah M.","year":"2017","unstructured":"Shah M.; Edman M.C.; Reddy Janga S.; Rapamycin eye drops suppress lacrimal gland inflammation in a murine model of Sj\u00f6gren\u2019s Syndrome. Invest Ophthalmol Vis Sci 2017,58(1),372-385","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=69","first-page":"5323","volume":"51","author":"Velagaleti P.","year":"2010","unstructured":"Velagaleti P.; Gilger B.; Anglade E.; Mitra A.A.; Clear, mixed nanomicellar formulation of voclosporin (LX214), achieves therapeutic levels in ocular posterior segment after single and multiple topical dosing in rabbits. Invest Ophthalmol Vis Sci 2010,51(13),5323","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1208\/s12249-014-0159-y","volume":"15","author":"Cholkar K.","year":"2014","unstructured":"Cholkar K.; Hariharan S.; Gunda S.; Mitra A.K.; Optimization of dexamethasone mixed nanomicellar formulation. AAPS PharmSciTech 2014,15(6),1454-1467","journal-title":"AAPS PharmSciTech"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1208\/s12249-014-0244-2","volume":"16","author":"Cholkar K.","year":"2015","unstructured":"Cholkar K.; Gunda S.; Earla R.; Pal D.; Mitra A.K.; Nanomicellar topical aqueous drop formulation of rapamycin for back-of-the-eye delivery. AAPS PharmSciTech 2015,16(3),610-622","journal-title":"AAPS PharmSciTech"},{"key":"ref=72","author":"Mitra A.K.","year":"2013","unstructured":"Mitra A.K.; Velagaleti P.R.; Natesan S.; Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors. United States patent US 8,435,544 2013"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/tvst.4.3.1","volume":"4","author":"Cholkar K.","year":"2015","unstructured":"Cholkar K.; Gilger B.C.; Mitra A.K.; Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Transl Vis Sci Technol 2015,4(3),1","journal-title":"Transl Vis Sci Technol"},{"key":"ref=74","first-page":"2677","volume":"59","author":"Weiss S.L.","year":"2018","unstructured":"Weiss S.L.; Kramer W.; Velagaleti P.; Gilger B.C.; ocular distribution of cyclosporine following topical administration of OTX-101 in New Zealand white rabbits. Invest Ophthalmol Vis Sci 2018,59(9),2677","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2147\/OPTH.S175065","volume":"12","author":"Tauber J.","year":"2018","unstructured":"Tauber J.; Schechter B.A.; Bacharach J.; A Phase II\/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clin Ophthalmol 2018,12,1921-1929","journal-title":"Clin Ophthalmol"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","volume":"126","author":"Goldberg D.F.","year":"2019","unstructured":"Goldberg D.F.; Malhotra R.P.; Schechter B.A.; Justice A.; Weiss S.L.; Sheppard J.D.; A Phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology 2019,126(9),1230-1237","journal-title":"Ophthalmology"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijpharm.2015.12.037","volume":"498","author":"Cholkar K.","year":"2016","unstructured":"Cholkar K.; Gilger B.C.; Mitra A.K.; Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm 2016,498(1-2),326-334","journal-title":"Int J Pharm"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0168-3659(02)00009-3","volume":"82","author":"Kabanov A.V.","year":"2002","unstructured":"Kabanov A.V.; Batrakova E.V.; Alakhov V.Y.; Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002,82(2-3),189-212","journal-title":"J Control Release"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jconrel.2008.04.013","volume":"130","author":"Batrakova E.V.","year":"2008","unstructured":"Batrakova E.V.; Kabanov A.V.; Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008,130(2),98-106","journal-title":"J Control Release"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/jop.2010.0048","volume":"26","author":"Boddu S.H.","year":"2010","unstructured":"Boddu S.H.; Jwala J.; Chowdhury M.R.; Mitra A.K.; In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using Doxorubicin as a model drug. J Ocul Pharmacol Ther 2010,26(5),459-468","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ijpharm.2011.01.004","volume":"416","author":"Di Tommaso C.","year":"2011","unstructured":"Di Tommaso C.; Torriglia A.; Furrer P.; Behar-Cohen F.; Gurny R.; M\u00f6ller M.; Ocular biocompatibility of novel cyclosporin a formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers. Int J Pharm 2011,416(2),515-524","journal-title":"Int J Pharm"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1167\/iovs.11-8829","volume":"53","author":"Di Tommaso C.","year":"2012","unstructured":"Di Tommaso C.; Valamanesh F.; Miller F.; A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. Invest Ophthalmol Vis Sci 2012,53(4),2292-2299","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=83","author":"Tsinman O","unstructured":"Tsinman O; Tsinman K; Ali S.; Excipient update- Soluplus\u00ae: an understanding of supersaturation from amorphous solid dispersions. Drug Delivery Technology 2015; 15(1)."},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.ejpb.2013.08.003","volume":"85","author":"Yu H.","year":"2013","unstructured":"Yu H.; Xia D.; Zhu Q.; Zhu C.; Chen D.; Gan Y.; Supersaturated polymeric micelles for oral cyclosporine A delivery. Eur J Pharm Biopharm 2013,85(3 Pt B),1325-1336","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"12968","DOI":"10.1038\/srep12968","volume":"5","author":"Guo C.","year":"2015","unstructured":"Guo C.; Zhang Y.; Yang Z.; Nanomicelle formulation for topical delivery of cyclosporine A into the cornea: in vitro mechanism and in vivo permeation evaluation. Sci Rep 2015,5,12968","journal-title":"Sci Rep"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1016\/j.xphs.2016.03.006","volume":"105","author":"Alvarez-Rivera F.","year":"2016","unstructured":"Alvarez-Rivera F.; Fern\u00e1ndez-Villanueva D.; Concheiro A.; Alvarez-Lorenzo C.; \u03b1-Lipoic acid in soluplus\u00ae polymeric nanomicelles for ocular treatment of diabetes-associated corneal diseases. J Pharm Sci 2016,105(9),2855-2863","journal-title":"J Pharm Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","volume":"248","author":"Mandal A.","year":"2017","unstructured":"Mandal A.; Bisht R.; Rupenthal I.D.; Mitra A.K.; Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies. J Control Release 2017,248,96-116","journal-title":"J Control Release"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1080\/10717544.2018.1458923","volume":"25","author":"Yu Y.","year":"2018","unstructured":"Yu Y.; Chen D.; Li Y.; Yang W.; Tu J.; Shen Y.; Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies. Drug Deliv 2018,25(1),888-899","journal-title":"Drug Deliv"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"8281","DOI":"10.2147\/IJN.S173691","volume":"13","author":"Shen Y.","year":"2018","unstructured":"Shen Y.; Yu Y.; Chaurasiya B.; Stability, safety, and transcorneal mechanistic studies of ophthalmic lyophilized cyclosporine-loaded polymeric micelles. Int J Nanomedicine 2018,13,8281-8296","journal-title":"Int J Nanomedicine"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.2147\/IJN.S158696","volume":"13","author":"Zhou Q.","year":"2018","unstructured":"Zhou Q.; Zhang L.; Yang T.; Wu H.; Stimuli-responsive polymeric micelles for drug delivery and cancer therapy. Int J Nanomedicine 2018,13,2921-2942","journal-title":"Int J Nanomedicine"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0169-409X(00)00124-1","volume":"47","author":"Kataoka K.","year":"2001","unstructured":"Kataoka K.; Harada A.; Nagasaki Y.; Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001,47(1),113-131","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1021\/ma971277v","volume":"31","author":"Harada A.","year":"1998","unstructured":"Harada A.; Kataoka K.; Novel polyion complex micelles entrapping enzyme molecules in the core: preparation of narrowly-distributed micelles from lysozyme and poly (ethylene glycol)-poly (aspartic acid) block copolymer in aqueous medium. Macromolecules 1998,31(2),288-294","journal-title":"Macromolecules"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jconrel.2003.05.002","volume":"93","author":"Zhang G-D.","year":"2003","unstructured":"Zhang G-D.; Harada A.; Nishiyama N.; Polyion complex micelles entrapping cationic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer. J Control Release 2003,93(2),141-150","journal-title":"J Control Release"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1021\/jp044766n","volume":"109","author":"Castro E.","year":"2005","unstructured":"Castro E.; Taboada P.; Mosquera V.; Behavior of a styrene oxide-ethylene oxide diblock copolymer\/surfac tant system: a thermodynamic and spectroscopy study. J Phys Chem B 2005,109(12),5592-5599","journal-title":"J Phys Chem B"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/1877912311202020096","volume":"2","author":"Boddu S.H.","year":"2012","unstructured":"Boddu S.H.; Polymeric Nanoparticles for ophthalmic drug delivery: an update on research and patenting activity. Recent Pat Nanomed 2012,2(2),96-112","journal-title":"Recent Pat Nanomed"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"278","DOI":"10.18433\/J3DP43","volume":"17","author":"Almeida H.","year":"2014","unstructured":"Almeida H.; Amaral M.H.; Lob\u00e3o P.; Silva A.C.; Loboa J.M.S.; Applications of polymeric and lipid nanoparticles in ophthalmic pharmaceutical formulations: present and future considerations. J Pharm Pharm Sci 2014,17(3),278-293","journal-title":"J Pharm Pharm Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/138920007779815977","volume":"8","author":"Bu H-Z.","year":"2007","unstructured":"Bu H-Z.; Gukasyan H.J.; Goulet L.; Lou X-J.; Xiang C.; Koudriakova T.; Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab 2007,8(2),91-107","journal-title":"Curr Drug Metab"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1023\/A:1018977130559","volume":"10","author":"Losa C.","year":"1993","unstructured":"Losa C.; Marchal-Heussler L.; Orallo F.; Vila Jato J.L.; Alonso M.J.; Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm Res 1993,10(1),80-87","journal-title":"Pharm Res"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.2042-7158.1991.tb03534.x","volume":"43","author":"Losa C.","year":"1991","unstructured":"Losa C.; Calvo P.; Castro E.; Vila-Jato J.L.; Alonso M.J.; Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles. J Pharm Pharmacol 1991,43(8),548-552","journal-title":"J Pharm Pharmacol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nnano.2007.387","volume":"2","author":"Peer D.","year":"2007","unstructured":"Peer D.; Karp J.M.; Hong S.; Farokhzad O.C.; Margalit R.; Langer R.; Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007,2(12),751-760","journal-title":"Nat Nanotechnol"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/gt.2012.56","volume":"20","author":"Contreras-Ruiz L.","year":"2012","unstructured":"Contreras-Ruiz L.; Zorzi G.K.; Hileeto D.; A nanomedicine to treat ocular surface inflammation: performance on an experimental dry eye murine model. Gene Therapy 2012,20,467","journal-title":"Gene Therapy"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.2147\/IJN.S173198","volume":"13","author":"Huang H-Y.","year":"2018","unstructured":"Huang H-Y.; Wang M-C.; Chen Z-Y.; Gelatin-epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief. Int J Nanomedicine 2018,13,7251-7273","journal-title":"Int J Nanomedicine"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1039\/C9NR00376B","volume":"11","author":"Li Y-J.","year":"2019","unstructured":"Li Y-J.; Luo L-J.; Harroun S.G.; Synergistically dual-functional nano eye-drops for simultaneous anti inflammatory and anti-oxidative treatment of dry eye disease. Nanoscale 2019,11(12),5580-5594","journal-title":"Nanoscale"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0378-5173(01)00760-8","volume":"224","author":"De Campos A.M.","year":"2001","unstructured":"De Campos A.M.; S\u00e1nchez A.; Alonso M.J.; Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001,224(1-2),159-168","journal-title":"Int J Pharm"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/02652048.2013.805839","volume":"31","author":"Basaran E.","year":"2014","unstructured":"Basaran E.; Yenilmez E.; Berkman M.S.; Buyukkoroglu G.; Yazan Y.; Chitosan nanoparticles for ocular delivery of cyclosporine A. J Microencapsul 2014,31(1),49-57","journal-title":"J Microencapsul"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1023\/A:1016015803611","volume":"13","author":"Calvo P.","year":"1996","unstructured":"Calvo P.; S\u00e1nchez A.; Mart\u00ednez J.; Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm Res 1996,13(2),311-315","journal-title":"Pharm Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1076\/ceyr.17.1.39.5251","volume":"17","author":"Juber\u00edas J.R.","year":"1998","unstructured":"Juber\u00edas J.R.; Calonge M.; G\u00f3mez S.; Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat. Curr Eye Res 1998,17(1),39-46","journal-title":"Curr Eye Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.exer.2008.04.002","volume":"87","author":"Yenice I.","year":"2008","unstructured":"Yenice I.; Mocan M.C.; Palaska E.; Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Exp Eye Res 2008,87(3),162-167","journal-title":"Exp Eye Res"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/jop.2009.0074","volume":"26","author":"Boddu S.H.S.","year":"2010","unstructured":"Boddu S.H.S.; Jwala J.; Vaishya R.; Novel nanoparticulate gel formulations of steroids for the treatment of macular edema. J Ocul Pharmacol Ther 2010,26(1),37-48","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/683153","volume":"2014","author":"Wagh V.D.","year":"2014","unstructured":"Wagh V.D.; Apar D.U.; Cyclosporine a loaded PLGA nanoparticles for dry eye disease: in vitro characterization studies. J Nanotechnol 2014,2014,1-10","journal-title":"J Nanotechnol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jconrel.2011.01.010","volume":"151","author":"Aksungur P.","year":"2011","unstructured":"Aksungur P.; Demirbilek M.; Denkba\u015f E.B.; Vandervoort J.; Ludwig A.; Unl\u00fc N.; Development and characterization of cyclosporine a loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies. J Control Release 2011,151(3),286-294","journal-title":"J Control Release"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejpb.2012.05.003","volume":"82","author":"Hermans K.","year":"2012","unstructured":"Hermans K.; Van den Plas D.; Everaert A.; Weyenberg W.; Ludwig A.; Full factorial design, physicochemical characterisation and biological assessment of cyclosporine A loaded cationic nanoparticles. Eur J Pharm Biopharm 2012,82(1),27-35","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12274-014-0547-3","volume":"8","author":"Liu S.","year":"2015","unstructured":"Liu S.; Chang C.N.; Verma M.S.; Phenylboronic acid modified mucoadhesive nanoparticle drug carriers facilitate weekly treatment of experimentally induced dry eye syndrome. Nano Res 2015,8(2),621-635","journal-title":"Nano Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3109\/02652049709033830","volume":"14","author":"Le Bourlais C.A.","year":"1997","unstructured":"Le Bourlais C.A.; Chevanne F.; Turlin B.; Effect of cyclosporine a formulations on bovine corneal absorption: ex-vivo study. J Microencapsul 1997,14(4),457-467","journal-title":"J Microencapsul"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ijpharm.2018.12.057","volume":"557","author":"Wen Z.","year":"2019","unstructured":"Wen Z.; Muratomi N.; Huang W.; The ocular pharmacokinetics and biodistribution of phospho sulindac (OXT-328) formulated in nanoparticles: enhanced and targeted tissue drug delivery. Int J Pharm 2019,557,273-279","journal-title":"Int J Pharm"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/187221108784534081","volume":"2","author":"Sawant K.K.","year":"2008","unstructured":"Sawant K.K.; Dodiya S.S.; Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv Formul 2008,2(2),120-135","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","volume":"47","author":"Mehnert W.","year":"2001","unstructured":"Mehnert W.; M\u00e4der K.; Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001,47(2-3),165-196","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1773-2247(08)50055-4","volume":"18","author":"Niu M.","year":"2008","unstructured":"Niu M.; Shi K.; Sun Y.; Wang J.; Cui F.; Preparation of CyA-loaded solid lipid nanoparticles and application on ocular preparations. J Drug Deliv Sci Technol 2008,18(4),293-297","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1089\/jop.2008.0031","volume":"24","author":"Kaur I.P.","year":"2008","unstructured":"Kaur I.P.; Rana C.; Singh H.; Development of effective ocular preparations of antifungal agents. J Ocul Pharmacol Ther 2008,24(5),481-493","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/pharmaceutics10040191","volume":"10","author":"Mishra V.","year":"2018","unstructured":"Mishra V.; Bansal K.K.; Verma A.; Solid lipid nanoparticles: emerging colloidal nano drug delivery systems. Pharmaceutics 2018,10(4),191","journal-title":"Pharmaceutics"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4103\/2230-973X.167661","volume":"5","author":"Khan S.","year":"2015","unstructured":"Khan S.; Baboota S.; Ali J.; Khan S.; Narang R.S.; Narang J.K.; Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig 2015,5(4),182-191","journal-title":"Int J Pharm Investig"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jconrel.2009.04.021","volume":"137","author":"Shen J.","year":"2009","unstructured":"Shen J.; Wang Y.; Ping Q.; Xiao Y.; Huang X.; Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release 2009,137(3),217-223","journal-title":"J Control Release"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.10.008","volume":"402","author":"Shen J.","year":"2010","unstructured":"Shen J.; Deng Y.; Jin X.; Ping Q.; Su Z.; Li L.; Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution. Int J Pharm 2010,402(1-2),248-253","journal-title":"Int J Pharm"},{"key":"ref=124","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/25\/12\/125101","volume":"25","author":"Zhang W.","year":"2014","unstructured":"Zhang W.; Wang Y.; Lee B.T.K.; Liu C.; Wei G.; Lu W.; A novel nanoscale-dispersed eye ointment for the treatment of dry eye disease. Nanotechnology 2014,25(12)","journal-title":"Nanotechnology"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/ICO.0000000000001867","volume":"38","author":"Niamprem P.","year":"2019","unstructured":"Niamprem P.; Teapavarapruk P.; Srinivas S.P.; Tiyaboonchai W.; Impact of nanostructured lipid carriers as an artificial tear film in a rabbit evaporative dry eye model. Cornea 2019,38(4),485-491","journal-title":"Cornea"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3762\/bjoc.8.39","volume":"8","author":"Nealon G.L.","year":"2012","unstructured":"Nealon G.L.; Greget R.; Dominguez C.; Liquid-crystalline nanoparticles: hybrid design and mesophase structures. Beilstein J Org Chem 2012,8(1),349-370","journal-title":"Beilstein J Org Chem"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/21680396.2017.1361874","volume":"5","author":"Mo J.","year":"2017","unstructured":"Mo J.; Milleret G.; Nagaraj M.; Liquid crystal nanoparticles for commercial drug delivery. Liquid Cryst Rev 2017,5(2),69-85","journal-title":"Liquid Cryst Rev"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3109\/1061186X.2012.723214","volume":"20","author":"Chen Y.","year":"2012","unstructured":"Chen Y.; Lu Y.; Zhong Y.; Wang Q.; Wu W.; Gao S.; Ocular delivery of cyclosporine A based on glyceryl monooleate\/poloxamer 407 liquid crystalline nanoparticles: preparation, characterization, in vitro corneal penetration and ocular irritation. J Drug Target 2012,20(10),856-863","journal-title":"J Drug Target"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1023\/A:1020398624602","volume":"19","author":"Quintana A.","year":"2002","unstructured":"Quintana A.; Raczka E.; Piehler L.; Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 2002,19(9),1310-1316","journal-title":"Pharm Res"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1021\/bc010102u","volume":"13","author":"Ihre H.R.","year":"2002","unstructured":"Ihre H.R.; Padilla De Jes\u00fas O.L.; Szoka F.C.; Fr\u00e9chet J.M.; Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjug Chem 2002,13(3),443-452","journal-title":"Bioconjug Chem"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/jps.2600640811","volume":"64","author":"Patton T.F.","year":"1975","unstructured":"Patton T.F.; Robinson J.R.; Ocular evaluation of polyvinyl alcohol vehicle in rabbits. J Pharm Sci 1975,64(8),1312-1316","journal-title":"J Pharm Sci"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0378-5173(99)00463-9","volume":"197","author":"Milhem O.M.","year":"2000","unstructured":"Milhem O.M.; Myles C.; McKeown N.B.; Attwood D.; D\u2019Emanuele A.; Polyamidoamine Starburst dendrimers as solubility enhancers. Int J Pharm 2000,197(1-2),239-241","journal-title":"Int J Pharm"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0378-5173(03)00132-7","volume":"257","author":"Bhadra D.","year":"2003","unstructured":"Bhadra D.; Bhadra S.; Jain S.; Jain N.K.; A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 2003,257(1-2),111-124","journal-title":"Int J Pharm"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jconrel.2003.07.001","volume":"93","author":"Ooya T.","year":"2003","unstructured":"Ooya T.; Lee J.; Park K.; Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J Control Release 2003,93(2),121-127","journal-title":"J Control Release"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1002\/chem.201504355","volume":"22","author":"Richichi B.","year":"2016","unstructured":"Richichi B.; Baldoneschi V.; Burgalassi S.; A divalent PAMAM-based matrix metalloproteinase\/carbonic anhydrase inhibitor for the treatment of dry eye syndrome. Chemistry 2016,22(5),1714-1721","journal-title":"Chemistry"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jtos.2018.05.004","volume":"16","author":"Lin H.","year":"2018","unstructured":"Lin H.; Liu Y.; Kambhampati S.P.; Hsu C-C.; Kannan R.M.; Yiu S.C.; Subconjunctival dendrimer-drug therapy for the treatment of dry eye in a rabbit model of induced autoimmune dacryoadenitis. Ocul Surf 2018,16(4),415-423","journal-title":"Ocul Surf"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1139\/cjc-2017-0193","volume":"95","author":"Lancina M.G.","year":"2017","unstructured":"Lancina M.G.; Yang H.; Dendrimers for ocular drug delivery. Can J Chem 2017,95(9),897-902","journal-title":"Can J Chem"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3109\/17435390.2016.1153165","volume":"10","author":"Mehra N.K.","year":"2016","unstructured":"Mehra N.K.; Cai D.; Kuo L.; Hein T.; Palakurthi S.; Safety and toxicity of nanomaterials for ocular drug delivery applications. Nanotoxicology 2016,10(7),836-860","journal-title":"Nanotoxicology"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jconrel.2015.07.007","volume":"213","author":"Coursey T.G.","year":"2015","unstructured":"Coursey T.G.; Henriksson J.T.; Marcano D.C.; Dexamethasone nanowafer as an effective therapy for dry eye disease. J Control Release 2015,213,168-174","journal-title":"J Control Release"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1021\/nn506599f","volume":"9","author":"Yuan X.","year":"2015","unstructured":"Yuan X.; Marcano D.C.; Shin C.S.; Ocular drug delivery nanowafer with enhanced therapeutic efficacy. ACS Nano 2015,9(2),1749-1758","journal-title":"ACS Nano"},{"key":"ref=141","author":"John M","unstructured":"John M; Gacche RN; Nano-formulations for ophthalmic treatments. Arch Pharm Pharma Sci 2017; 1: 028-035."},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.ophtha.2017.07.010","volume":"124","author":"Pflugfelder S.C.","year":"2017","unstructured":"Pflugfelder S.C.; de Paiva C.S.; The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology 2017,124(11S),S4-S13","journal-title":"Ophthalmology"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1089\/jop.2018.0031","volume":"35","author":"Rangarajan R.","year":"2019","unstructured":"Rangarajan R.; Ketelson H.; Preclinical evaluation of a new hydroxypropyl guar phospholipid nanoemulsion based artificial tear formulation in models of corneal epithelium. J Ocul Pharmacol Ther 2019,35(1),32-37","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1089\/jop.2016.0164","volume":"33","author":"Kim H.S.","year":"2017","unstructured":"Kim H.S.; Kim T.I.; Kim J.H.; Evaluation of clinical efficacy and safety of a novel Cyclosporin a Nanoemulsion in the treatment of dry eye syndrome. J Ocul Pharmacol Ther 2017,33(7),530-538","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.colsurfb.2016.08.048","volume":"148","author":"Akhter S.","year":"2016","unstructured":"Akhter S.; Anwar M.; Siddiqui M.A.; Improving the topical ocular pharmacokinetics of an immunosuppressant agent with mucoadhesive nanoemulsions: formulation development, in-vitro and in-vivo studies. Colloids Surf B Biointerfaces 2016,148,19-29","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.colsurfb.2018.09.063","volume":"173","author":"Lidich N.","year":"2019","unstructured":"Lidich N.; Garti-Levy S.; Aserin A.; Garti N.; Potentiality of microemulsion systems in treatment of ophthalmic disorders: keratoconus and dry eye syndrome - in vivo study. Colloids Surf B Biointerfaces 2019,173,226-232","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jcis.2015.10.024","volume":"463","author":"Lidich N.","year":"2016","unstructured":"Lidich N.; Aserin A.; Garti N.; Structural characteristics of oil-poor dilutable fish oil omega-3 microemulsions for ophthalmic applications. J Colloid Interface Sci 2016,463,83-92","journal-title":"J Colloid Interface Sci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1021\/mp400484g","volume":"11","author":"Rahman Z.","year":"2014","unstructured":"Rahman Z.; Xu X.; Katragadda U.; Krishnaiah Y.S.R.; Yu L.; Khan M.A.; Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion. Mol Pharm 2014,11(3),787-799","journal-title":"Mol Pharm"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1182\/bloodadvances.2018028431","volume":"3","author":"Ohigashi H.","year":"2019","unstructured":"Ohigashi H.; Hashimoto D.; Hayase E.; Ocular instillation of vitamin A-coupled liposomes containing HSP47 siRNA ameliorates dry eye syndrome in chronic GVHD. Blood Adv 2019,3(7),1003-1010","journal-title":"Blood Adv"},{"key":"ref=150","first-page":"18","volume":"64","author":"Shimokawa T.","year":"2018","unstructured":"Shimokawa T.; Yoshida M.; Fukuta T.; Tanaka T.; Inagi T.; Kogure K.; Efficacy of high-affinity liposomal astaxanthin on up-regulation of age-related markers induced by oxidative stress in human corneal epithelial cells. J Clin Biochem Nutr 2018,64(1),18-27","journal-title":"J Clin Biochem Nutr"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1021\/acs.molpharmaceut.8b00516","volume":"15","author":"Ren T.","year":"2018","unstructured":"Ren T.; Lin X.; Zhang Q.; Encapsulation of azithromycin ion pair in liposome for enhancing ocular delivery and therapeutic efficacy on dry eye. Molecular pharmaceutics 2018,15(11),4862-4871","journal-title":"Molecular pharmaceutics"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.clae.2017.11.004","volume":"41","author":"Acar D.","year":"2018","unstructured":"Acar D.; Molina-Mart\u00ednez I.T.; G\u00f3mez-Ballesteros M.; Guzm\u00e1n-Navarro M.; Ben\u00edtez-del-Castillo J.M.; Herrero-Vanrell R.; Novel liposome-based and in situ gelling artificial tear formulation for dry eye disease treatment. Cont Lens Anterior Eye 2018,41(1),93-96","journal-title":"Cont Lens Anterior Eye"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.exer.2016.11.010","volume":"154","author":"Soriano-Roman\u00ed L.","year":"2017","unstructured":"Soriano-Roman\u00ed L.; Vicario-de-la-Torre M.; Crespo-Moral M.; Novel anti-inflammatory liposomal formulation for the pre-ocular tear film: in vitro and ex vivo functionality studies in corneal epithelial cells. Experim Eye Res 2017,154,79-87","journal-title":"Experim Eye Res"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"7839","DOI":"10.1167\/iovs.14-14700","volume":"55","author":"Vicario-de-la-Torre M.","year":"2014","unstructured":"Vicario-de-la-Torre M.; Ben\u00edtez-del-Castillo J.M.; Vico E.; Design and characterization of an ocular topical liposomal preparation to replenish the lipids of the tear film. Invest Ophthalmol Vis Sci 2014,55(12),7839-7847","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clae.2012.05.003","volume":"35","author":"Pult H.","year":"2012","unstructured":"Pult H.; Gill F.; Riede-Pult B.H.; Effect of three different liposomal eye sprays on ocular comfort and tear film. Cont Lens Anterior Eye 2012,35(5),203-207","journal-title":"Cont Lens Anterior Eye"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1463-5224.2010.00834.x","volume":"14","author":"Shafaa M.W.","year":"2011","unstructured":"Shafaa M.W.; El Shazly L.H.; El Shazly A.H.; El gohary AA, El hossary GG. Efficacy of topically applied liposome-bound tetracycline in the treatment of dry eye model. Vet Ophthalmol 2011,14(1),18-25","journal-title":"Vet Ophthalmol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.clae.2009.12.007","volume":"33","author":"Craig J.P.","year":"2010","unstructured":"Craig J.P.; Purslow C.; Murphy P.J.; Wolffsohn J.S.W.; Effect of a liposomal spray on the pre-ocular tear film. Contact Lens Anterior Eye 2010,33(2),83-87","journal-title":"Contact Lens Anterior Eye"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biomaterials.2017.02.016","volume":"125","author":"Soiberman U.","year":"2017","unstructured":"Soiberman U.; Kambhampati S.P.; Wu T.; Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation. Biomaterials 2017,125,38-53","journal-title":"Biomaterials"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2015.11.059","volume":"140","author":"Yingfang F.","year":"2016","unstructured":"Yingfang F.; Zhuang B.; Wang C.; Xu X.; Xu W.; Lv Z.; Pimecrolimus micelle exhibits excellent therapeutic effect for Keratoconjunctivitis Sicca. Colloids Surf B Biointerfaces 2016,140,1-10","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1021\/acs.molpharmaceut.7b00939","volume":"15","author":"Grimaudo M.A.","year":"2018","unstructured":"Grimaudo M.A.; Pescina S.; Padula C.; Poloxamer 407\/tpgs mixed micelles as promising carriers for cyclosporine ocular delivery. Mol Pharmaceutics 2018,15(2),571-584","journal-title":"Mol Pharmaceutics"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1021\/acs.biomac.6b00054","volume":"17","author":"Prosperi-Porta G","year":"2016","unstructured":"Prosperi-Porta G; Kedzior S; Muirhead B; Sheardown H;  Phenylboronic-acid-based polymeric micelles for mucoadhesive anterior segment ocular drug delivery. Biomacromolecules 2016,17(4),1449-57. 2016\/04\/11","journal-title":"Biomacromolecules"},{"key":"ref=162","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijpharm.2013.07.002","volume":"455","author":"Luschmann C.","year":"2013","unstructured":"Luschmann C.; Herrmann W.; Strau\u00df O.; Luschmann K.; Goepferich A.; Ocular delivery systems for poorly soluble drugs: an in-vivo evaluation. Int J Pharmaceutics 2013,455(1),331-337","journal-title":"Int J Pharmaceutics"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.colsurfb.2012.10.055","volume":"103","author":"Ribeiro A.","year":"2013","unstructured":"Ribeiro A.; Sandez-Macho I.; Casas M.; Alvarez-P\u00e9rez S.; Alvarez-Lorenzo C.; Concheiro A.; Poloxamine micellar solubilization of \u03b1-tocopherol for topical ocular treatment. Colloids Surf B Biointerfaces 2013,103,550-557","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijpharm.2011.01.004","volume":"416","author":"Di Tommaso C.","year":"2011","unstructured":"Di Tommaso C.; Torriglia A.; Furrer P.; Behar-Cohen F.; Gurny R.; M\u00f6ller M.; Ocular biocompatibility of novel cyclosporin a formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers. Int J Pharm 2011,416(2),515-524","journal-title":"Int J Pharm"},{"key":"ref=165","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1039\/C9NR00376B","volume":"12","author":"Li Y-J.","year":"2019","unstructured":"Li Y-J.; Luo L-J.; Harroun S.G.; Synergistically dual-functional nano eye-drops for simultaneously anti-inflammatory and anti-oxidative treatment of dry eye disease. Nanoscale 2019,12,5580-5594","journal-title":"Nanoscale"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ijpharm.2017.07.044","volume":"529","author":"J\u00f3hannsd\u00f3ttir S.","year":"2017","unstructured":"J\u00f3hannsd\u00f3ttir S.; Kristinsson J.K.; F\u00fcl\u00f6p Z.; \u00c1sgr\u00edmsd\u00f3ttir G.; Stef\u00e1nsson E.; Loftsson T.; Formulations and toxicologic in vivo studies of aqueous cyclosporin a eye drops with cyclodextrin nanoparticles. Int J Pharmaceutics 2017,529(1),486-490","journal-title":"Int J Pharmaceutics"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.colsurfb.2017.05.064","volume":"157","author":"Maulvi F.A.","year":"2017","unstructured":"Maulvi F.A.; Choksi H.H.; Desai A.R.; pH triggered controlled drug delivery from contact lenses: addressing the challenges of drug leaching during sterilization and storage. Colloids Surf B Biointerfaces 2017,157,72-82","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1167\/iovs.16-20843","volume":"58","author":"Lee H.","year":"2017","unstructured":"Lee H.; Shim W.; Kim C.E.; Choi S.Y.; Lee H.; Yang J.; Therapeutic efficacy of nanocomplex of poly (ethylene glycol) and catechin for dry eye disease in a mouse model. Invest Ophthalmol Vis Sci 2017,58(3),1682-1691","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1021\/acs.molpharmaceut.6b00445","volume":"13","author":"Liu S.","year":"2016","unstructured":"Liu S.; Dozois M.D.; Chang C.N.; Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables treatment of eye diseases using significantly reduced dosage. Mol Pharm 2016,13(9),2897-2905","journal-title":"Mol Pharm"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3109\/10717544.2016.1172368","volume":"23","author":"Yavuz B.","year":"2016","unstructured":"Yavuz B.; Bozda\u011f Pehlivan S.; Kaffashi A.; In vivo tissue distribution and efficacy studies for cyclosporin A loaded nano-decorated subconjunctival implants. Drug Deliv 2016,23(9),3279-3284","journal-title":"Drug Deliv"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jconrel.2014.12.017","volume":"208","author":"Hsueh P-Y.","year":"2015","unstructured":"Hsueh P-Y.; Edman M.C.; Sun G.; Shi P.; Xu S.; Lin Y-a.; Tear-mediated delivery of nanoparticles through transcytosis of the lacrimal gland. J Control Release 2015,208,2-13","journal-title":"J Control Release"},{"key":"ref=172","first-page":"32","volume":"69","author":"Hermans K.","year":"2014","unstructured":"Hermans K.; Van Den Plas D.; Schreurs E.; Weyenberg W.; Ludwig A.; Cytotoxicity and anti-inflammatory activity of cyclosporine a loaded PLGA nanoparticles for ocular use. Pharmazie 2014,69(1),32-37","journal-title":"Pharmazie"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jconrel.2013.07.016","volume":"171","author":"Shah M","year":"2013","unstructured":"Shah M; Edman MC; Janga SR; A rapamycinbinding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sj\u00f6gren's syndrome. J Control Release 2013\/11\/10\/2013,171(3),269-279","journal-title":"J Control Release"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijpharm.2012.08.016","volume":"437","author":"Khan W.","year":"2012","unstructured":"Khan W.; Aldouby Y.H.; Avramoff A.; Domb A.J.; Cyclosporin nanosphere formulation for ophthalmic administration. Int J Pharmaceutics 2012,437(1),275-276","journal-title":"Int J Pharmaceutics"}],"container-title":["Pharmaceutical Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/183230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183230\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/183230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T19:06:08Z","timestamp":1615143968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183230\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":174,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2211738508666200628034227","relation":{},"ISSN":["2211-7385"],"issn-type":[{"value":"2211-7385","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}